BRAF mutations in non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 11, 2014, Pages 1594-1595

  Smit, Egbert ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; VEMURAFENIB;

CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL TRIAL (TOPIC); EDITORIAL; GENE MUTATION; GENETIC SCREENING; HUMAN; LUNG ADENOCARCINOMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SQUAMOUS CELL LUNG CARCINOMA; FEMALE; GENETICS; LUNG TUMOR; MALE; MUTATION;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84925714296     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000382     Document Type: Editorial

References (15)

1. Litvak A, Paik P, Woo K, et al. Clinical characteristics and course of 63 patients with B-RAF mutant lung cancers. J Thor Oncol 2014;9:1669-1674.
2. Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012;7:e23-e24.
3. Peters S, Michielin O, Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol 2013;31:e341-e344.
4. Planchard D, Mazieres J, Reily GJ, et al. Interim results of phase II study BRF113928 of dabrafenib in B-RAF V600E mutation-positive nonsmall cell lung cancer (NSCLC) patients. J Clin Oncol 2012;31(Suppl): abstr 8009,.
5. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
6. L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by signalling through the RAF/MEK/ERK pathway. Genes Dev 26,1945-1958,2012.
7. Sen B, Peng S, Tang X, et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med 2012;4:136ra70.
8. Chen D, Zhang L-Q, Huang J-F, et al. BRAF mutations in patients with non-small cell lung cancer: a systemic review and meta-analysis. PLoS One 2014;9:e101354.
9. Barlesi F, Blons H, Beau-Faller M, et al. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and ALK gene fusion assessment on the first 10.000 nonsmall cell lung cancer (NSCLC) patients (pts). Proc Am Soc Clin Oncol 2012;abstr 8000.
10. Pratilas CA, Hanrahan AJ, Halilovic E, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008;68:9375-9383.
11. Bunn PA, Doebele RC. Genetic testing for lung cancer: reflex versus clinical selection. J Clin Oncol 2011;29:1943-1945.
12. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011;29:3574-3579.
13. Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013;19:4532-4540.
14. Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF mutant non-small cell lung cancer. J Thor Oncol 2013;8:e41-42.
15. Lin L, Asthana S, Chan E, et al. Mapping the molecular determinants of BRAF oncogenen dependence in human lung cancer. Proc Natl Acad Sc 2014;111:E748-E757.